Dear Ms. Rockney:

Please refer to your supplemental new drug application dated November 22, 2002, received November 25, 2002, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Methotrexate Sodium for Injection, Methotrexate Sodium Injection.

This supplemental application provides for the addition of new precautions and adverse reactions, revised title and How Supplied section, and the addition of a Geriatric Use section.

We completed our review of this supplemental new drug application. It is approved, effective on the date of this letter, for use as recommended in the final printed labeling (FPL) submitted on November 22, 2002.

If you issue a letter communicating important information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Paul Zimmerman, Project Manager, at (301) 594-5775.

Sincerely,

{See appended electronic signature page}

Richard Pazdur, M.D.
Director
Division of Oncology Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/
---------------------
Richard Pazdur
1/3/03 09:54:03 AM